(Q37077695)

18 August 2017

1 reference

title

Palliative treatment of pancreatic cancer (English)

1 reference

18 August 2017

1 reference

1

Götz von Wichert

0 references

Thomas Seufferlein

series ordinal

2

object named as

Thomas Seufferlein

0 references

Guido Adler

series ordinal

3

object named as

Guido Adler

1 reference

18 August 2017

publication date

1 February 2008

1 reference

Journal of Digestive Diseases

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

1-7

1 reference

Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1443-9573.2007.00314.X

Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002093.PUB2

Identifiers

DOI

10.1111/J.1443-9573.2007.00314.X

1 reference

18 August 2017

1 reference